Marketing authorisation holder:
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
Netherlands
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local authority or to Incyte (by e-mail: eumedinfo@incyte.com).
DK/PEMA/P/23/0005
Date of preparation: January 2024
© 2024, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.
If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/
Intended for licensed healthcare professionals located in Denmark.
You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third–party sites. Would you like to continue?